Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × Sorafenib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Genitourinary 3 Tumor-Agnostic 1 Thoracic 1 Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33 Lung Neoplasms 14 Neoplasms 5 Adenocarcinoma of Lung 4 Carcinoma, Renal Cell 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Mesothelioma 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Adenocarcinoma, Bronchiolo-Alveolar 2 Solitary Fibrous Tumor, Pleural 1 Prostatic Neoplasms 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Mesothelioma, Malignant 1 Melanoma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Small Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1

Interventions

Carboplatin 22 Pemetrexed 17 Cisplatin 17 Paclitaxel 14 pembrolizumab 13 Gemcitabine 8 osimertinib 7 durvalumab 6 Docetaxel 6 Nivolumab 5 Erlotinib Hydrochloride 5 130-nm albumin-bound paclitaxel 4 capmatinib 3 brigatinib 3 anlotinib 3 Gefitinib 3 Drug Therapy 3 vosaroxin 2 volociximab 2 sintilimab 2 pralsetinib 2 ensartinib 2 atezolizumab 2 aflibercept 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Oncolytic Virotherapy 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00863746 2015-01-19

MISSION

Bayer

Phase 3 Completed

703 enrolled 25 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡